Efficacy and complications of argon plasma coagulation for hemorrhagic chronic radiation proctitis

Table 2 Univariate analysis of factors associated with argon plasma coagulation treatment complications for hemorrhagic chronic radiation proctitis

Variable	No. of complication/total patients	P-value
Distribution of telangiectasias
Distal rectum (within 10 cm from anal verge)	4/31	1.0002
Entire rectum +/− sigmoid (more than 10 cm from anal verge)	2/14
Surface area covered by telangiectasias
Less than 50%	2/19	1.0002
More than 50%	4/26
Presence of fresh blood
No	1/16	0.3992
Yes	5/29
Ulceration
< 1 cm2	2/33	0.0352
> 1 cm2	4/12
Gender
Female	5/40	0.5292
Male	1/5
Hypertensive
No	4/39	0.3671
Yes	2/6
Diabetic
No	4/40	0.1252
Yes	2/5
Abdominal surgery
No	6/33	0.1712
Yes	0/12
Acute radiation injury
No	6/39	0.6991
Yes	0/6
Requiring blood transfusions
No	3/30	0.3842
Yes	3/15
Number of APC
1	5/33	1.0002
≥ 2	1/12
Age, yr
< 60	1/22	0.1872
≥ 60	5/23
BMI at the first treatment of APC, kg/m2
< 21	3/21	1.0002
≥ 21	3/24
Time from the end of radiotherapy to bleeding, mo
< 8	2/17	1.0002
≥ 8	4/28
Time from the end of radiotherapy to the first time of APC, mo
< 14	4/23	0.6652
≥ 14	2/22

¹Data were calculated using continuity correction;

²Data were calculated using the Fisher exact test.

APC: Argon plasma coagulation; CRP: Chronic radiation proctitis; BMI: Body mass index.